Company News

Share this article:

Endo Pharmaceuticals announced a partnership with specialty pharma ProStrakan to commercialize the latter's Fortesta (testosterone gel) 2% in the US. FDA is currently reviewing an NDA for Fortesta, a hormone replacement therapy for male hypogonadism – a condition whereby male sex glands produce too little testosterone. Endo plans to market the product, upon FDA approval, alongside Nebido, an Endo hormone therapy injectable also under review at FDA.   

Behavioral science agency MicroMass Communications announced a partnership with Worldwide Partners, Inc. (WPI) to increase its reach internationally. WPI's network consists of 94 agencies for clients in 54 countries around the world. WPI is based in Denver, CO.

Abbott will collaborate with Pfizer on a molecular diagnostic test for the screening of non-small cell lung cancer tumors for the presence of gene rearrangements, according to a joint company statement. Abbott's molecular diagnostics business, headquartered in Des Plaines, IL, will develop the diagnostic tool necessary for identifying patients eligible for Pfizer's investigational agent (PF-02341066) that selectively targets cancer-causing genes, according to the statement.   


Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.